YKL-40 (Chitinase-3-Like Protein 1) Serum Levels in Aortic Stenosis

Identification of novel biomarkers could provide prognostic information and improve risk stratification in patients with aortic stenosis (AS). YKL-40 (chitinase-3-like protein 1), a protein involved in atherogenesis, is upregulated in human calcific aortic valves. We hypothesized that circulating YK...

Full description

Saved in:
Bibliographic Details
Published in:Circulation. Heart failure 2020-10, Vol.13 (10), p.e006643-e006643
Main Authors: Arain, Fizza, Abraityte, Aurelija, Bogdanova, Mariia, Solberg, Ole G., Michelsen, Annika E., Lekva, Tove, Aakhus, Svend, Holm, Sverre, Halvorsen, Bente, Finsen, Alexandra V., Vinge, Leif-Erik, Nymo, Ståle, Espeland, Torvald, Ranheim, Trine, Aukrust, Pål, Vaage, Ingvar Jarle, Auensen, Andreas, Gullestad, Lars, Ueland, Thor
Format: Article
Language:English
Subjects:
Aged
Aged, 80 and over
Animals
Aortic Valve - metabolism
Aortic Valve - pathology
Aortic Valve Stenosis - blood
Aortic Valve Stenosis - diagnosis
Aortic Valve Stenosis - genetics
Aortic Valve Stenosis - mortality
Biomarkers - blood
Cardiology: 771
Case-Control Studies
Chitinase-3-Like Protein 1 - blood
Chitinase-3-Like Protein 1 - genetics
Clinical medical disciplines: 750
Cross-Sectional Studies
Denmark
Disease Models, Animal
Female
Humans
Interleukin-13 Receptor alpha2 Subunit - genetics
Interleukin-13 Receptor alpha2 Subunit - metabolism
Kardiologi: 771
Klinisk medisinske fag: 750
Male
Medical disciplines: 700
Medisinske Fag: 700
Mice, Inbred C57BL
Middle Aged
Norway
Prognosis
Severity of Illness Index
Up-Regulation
VDP
Citations: Items that this one cites
Items that cite this one
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Identification of novel biomarkers could provide prognostic information and improve risk stratification in patients with aortic stenosis (AS). YKL-40 (chitinase-3-like protein 1), a protein involved in atherogenesis, is upregulated in human calcific aortic valves. We hypothesized that circulating YKL-40 would be elevated and associated with the degree of AS severity and outcome in patients with symptomatic AS. Plasma YKL-40 was analyzed in 2 AS populations, one severe AS (n=572) with outcome measures and one with mixed severity (n=67). YKL-40 expression in calcified valves and in an experimental pressure overload model was assessed. We found (1) patients with AS had upregulated circulating YKL-40 compared with healthy controls (median 109 versus 34 ng/mL,
ISSN:1941-3297
1941-3289
1941-3297
DOI:10.1161/CIRCHEARTFAILURE.119.006643